Figure 1From: Fractalkine (CX3CL1) enhances hippocampal N-methyl-d-aspartate receptor (NMDAR) function via d-serine and adenosine receptor type A2 (A2AR) activity CX 3 CL1 produces transient N -methyl- d -aspartate receptor (NMDAR) potentiation in CA1 pyramidal neurons (STP). Horizontal bar, CX3CL1 application (5 nM). (A) CX3CL1 increases NMDA-field excitatory postsynaptic potentials (fEPSPs) slope. Top: representative average traces of NMDA-fEPSPs recorded in control (1 minute before application), after 20 minutes of CX3CL1 treatment and at 20 minutes of withdrawal, as indicated. Vertical scale bar: 0.2 mV, horizontal scale bar: 20 ms. Bottom: average timecourse of CX3CL1-induced increase of the NMDA-fEPSPs slope in mouse hippocampal slices (n = 35/28). Here and thereafter each point represents the average of three responses evoked every 20 s, as detailed in Methods. (B) CX3CL1 increases the amplitude of evoked excitatory postsynaptic currents (EPSCs). Top: sample traces of EPSCs (average of three events over 1 minute) recorded before, after 20 minutes of chemokine application, and 20 minutes after washout, as indicated. Vertical scale bar: 20 pA, horizontal scale bar: 20 ms. Bottom: average timecourse of the current peak amplitude. Circles represent averages of three responses evoked every 20 s in five different slices (five mice).Back to article page